What Is the Connection between Valsartan and Amlodipine?

Valsartan amlodipine is a film-coated tablet. The film-coated tablet appears white when removed. It is used for the treatment of essential hypertension, and it is used for patients whose blood pressure cannot be fully controlled by monotherapy.

Valsartan amlodipine

Valsartan amlodipine is a film-coated tablet. The film-coated tablet appears white when removed. It is used for the treatment of essential hypertension, and it is used for patients whose blood pressure cannot be fully controlled by monotherapy.

Drug Name

Valsartan amlodipine

Foreign name

Valsartan and Amlodipine Tablets (I)

Main indications

This product is used for patients who cannot fully control blood pressure with single drug treatment.

Dosage form

Film-coated tablets

Product Name: Bebot

Common name: Valsartan Amlodipine Tablets (I)

English name: Valsartan and Amlodipine Tablets (I)

Chinese Pinyin: Xieshatan Anlüdiping Pian

Each tablet contains Valsartan 80mg and Amlodipine 5mg.

This product is a film-coated tablet. The film-coated tablet appears white when removed.

treatment

Amlodipine 2.5-10 mg once daily is effective in treating hypertension, while the effective dose of valsartan is 80-320 mg. In the clinical trial of Valsartan Amlodipine tablets once daily, 5-10 mg of amlodipine and 80-320 mg of valsartan, the antihypertensive effect increased with increasing dose.

Adverse effects of valsartan are usually dose-independent; adverse reactions of amlodipine are both dose-dependent (mainly peripheral edema) and dose-independent, the former being more common than the latter.

Patients who cannot fully control blood pressure with a single drug can use this product instead.

Additive treatment: In the case of amlodipine monotherapy or valsartan monotherapy, patients who have insufficient blood pressure control can switch to this product for combination therapy.

Patients who experience dose-limiting adverse reactions during amlodipine or valsartan monotherapy can switch to this product and use a lower dose of a single drug component in combination with another component to achieve blood pressure control.

Alternative treatment: For the convenience of administration, patients receiving amlodipine and valsartan monotherapy can switch to the same dose of this product for treatment.

Disable

No overdose of this product has been obtained. The main symptom of valsartan overdose may be hypotension accompanied by dizziness. Excessive amlodipine may cause excessive dilation of peripheral blood vessels and may cause reflex tachycardia. Significant and persistent systemic hypotension and fatal shock have been reported.

If the medication is not taken for a long time, vomiting or gastric lavage can be considered. Healthy volunteers taking activated carbon immediately after taking amlodipine or two hours later can significantly reduce amlodipine absorption. The clinically significant hypotension caused by the overdose of this product requires active and effective cardiovascular support treatment, including close monitoring of heart and respiratory function, elevation of limbs, and attention to circulating fluid volume and urine volume. In order to restore vascular tone and blood pressure, vasoconstrictor drugs can also be used when there are no contraindications. Reversal of intravenous infusion of calcium gluconate

Those who are allergic to the active ingredients of this product or any of the excipients are prohibited.

Pregnant and lactating women are contraindicated (see instructions for women's medication).

There are no data on medications in patients with severe renal impairment (creatinine clearance <10 ml / min).

Study of this product: The safety evaluation of valsartan amlodipine tablets was performed in more than 2600 hypertensive patients; more than 1,440 patients received treatment for more than 6 months, and more than 540 patients received more than 1 year the treatment. Adverse reactions are usually mild and transient, with very few cases requiring discontinuation.

The overall incidence of adverse reactions was non-dose-dependent and was independent of gender, age, and ethnicity. In a placebo-controlled clinical study, 1.8% of patients in the valsartan amlodipine tablets discontinued treatment due to side effects, compared with 2.1% of patients in the placebo group. The most common reasons for discontinuation were peripheral edema (0.4%) and dizziness (0.2%).

During pregnancy:

Given the mechanism of action of angiotensin II antagonists, its harm to the fetus cannot be ruled out. There have been reports of intrauterine administration at the 2nd and 3rd trimesters of pregnancy.

Import batch number H20090840

Novartis Pharma Schweiz AG, Switzerland